Home > Current

A Preliminary Phase-2 Study with very High-Dose of Melatonin (1000 mg/day) in Untreatable Advanced Cancer Patients Already Progression on Previous Palliative Therapy with High-Dose Melatonin

Paolo Lissoni （ Institute of Biological Medicine ）

Giorgio Porro （ Institute of Biological Medicine, Milan, Italy ）

Carla Galli （ Studio Medico Codogni,Verona , Italy ）

Rosalia Codogni （ Studio Medico Codogni,Verona , Italy ）

Nicoletta Merli （ Studio il Faro,Melegnano, Milan, Italy ）

Giuseppe Di Fede （ Institute of Biological Medicine, Milan, Italy ）

https://doi.org/10.37155/2717-5278-0202-1

Abstract

It is known since more than 50 years that the pineal gland plays a fundamental role in the natural biological resistance against cancer onset and growth. The anticancer role of the pineal gland is due to the production of several antitumor molecules, the most known of them is the indole hormone melatonin (MLT). Unfortunately, although there are a lot of experimental evidences that MLT is completely non-toxic, no oncologist seem to be interested to the clinical use of MLT in the treatment of human neoplasms, at least from a palliative point of view. However, a few number of clinical studies of MLT in the complementary treatment of cancer has demonstrated that the anticancer activity of MLT is a dose-dependent phenomenon. On this basis, a preliminary study with a very high dose of MLT, consisting of 1000 mg/once day in the evening, was carried out in untreatable cancer patients, who failed to respond to the conventional anticancer therapies, and for whom the only available treatment was the palliative therapy. The treatment was well tolerated, and a disease control was achieved in 54% patients. These preliminary results would justify further clinical studies to generate a new interpretation of cancer control, consisting of the pharmacological reproduction of the same mechanisms responsible for the natural resistance against cancer development.

Keywords

Cancer; melatonin; palliative therapy; pineal gland

Full Text

PDF

References

[1] Bartsch C, Bartsch H. Melatonin in cancer patients and in tumor-bearing animals. Adv Exp Med Biol 467: 247-264, 1999.
[2] Sze SF, Ng TB, Liu WK. Antiproliferative effect of pineal indoles on cultured tumor cell lines[J]. J Pineal Res, 1993, 14(1): 27-33.
[3] Maestroni GJM. The immunoneuroendocrine role of melatonin[J]. J Pineal Res, 1993, 14(1): 1-10.
[4] EA Grimm, RJ Robb, JA Roth, LM Neckers, LB Lachman, DJ Wilson, SA Rosenberg. Lymphokine-activated killer cell phenomenon.III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells[J]. J Exp Med, 1983,158(4): 1356-1361.
[5] Guerrero JM, Reiter RJ. Melatonin-immune system relationships[J]. Curr Topics Med Chem,2002,2(2): 167-179.
[6] Kuklina EM, Glebezdina NS, Nekrasova V. Role of melatonin in the regulation of differentiation of T cells producing interleukin-17 (Th17)[J]. Bull ExpBiol Med,2016, 160(5): 656-658.
[7] Wang YR, Hong RT, Xie YY, Xu JM. Melatonin ameliorates liver fibrosis induced by carbon tetrachloride in rats via inhibiting TGF-beta 1/Smad signalling pathway[J]. Curr Med Sci,2018, 38(2): 236-244.
[8] Lissoni P, Pittalis S, Rovelli F, Vigoré L, Roselli MG, Brivio F. Interleukin-2, melatonin and interleukin-12 as a possible neuroimmune combination in the biotherapy of cancer[J]. J Biol Regul Homeost Agents 1995,9(2): 63-66.
[9] Banks RE, Patel PM, Selby PJ. Interleukin 12: a new clinical player in cytokine therapy[J]. Br J Cancer 1995,71(4): 655-659.
[10] Regelson W, Pierpaoli W. Melatonin: a rediscovered antitumor hormone? Its Relation to Surface Receptors; Sex Steroid Metabolism, Immunologic Response, and Chronobiologic Factors in Tumor Growth and Therapy[J]. Cancer Invest,1987,5(4): 379-85.
[11] Buswell RS. The pineal and neoplasia. Lancet 1975, 305(7897): 34-35.
[12] Reiter RJ. Mechanisms of cancer inhibition by melatonin[J]. J Pineal Res, 2004, 37(3): 213-214.
[13] Vinken M, Henkens T, De Rop F, Fraczek J, Vanhaecke T, Rogiers V. Biology and pathology of gap junctional channel in hepatocytes[J]. Hepatology,2008, 47(3): 1077-1088.
[14] Park SY, Jang WJ, Yi EY, Jang JY, Jung Y, Jeong JW, Kim YJ. Melatonin suppresses tumor angiogenesis by inhibiting HIF- 1 alpha stabilization under hypoxia[J]. J Pineal Res 2010,48(2): 178-184.
[15] Valverde P, Benedito E, Solano F, Oaknin S, Lozano JA, Garcia-Borron JC. Melatonin antagonizes alpha-melanocyte-stimulating hormone enhancement of melanogenesis in mouse melanoma cells by blocking the hormone-induced accumulation of the c locus tyrosinase[J]. Eur J Biochem,1995 232(1): 257-263.
[16] Pedrosa AM, Weinlich R, Mognol GP, Robbs BK, Viola JP, Campa A, Amarante-Mendes GR. Melatonin protects CD4+ T cells from activation-induced cell death by blocking NFAT-mediated CD95 ligand up-regulation[J]. J Immunol,2010, 184(7): 3487-3494.
[17] Lissoni P, Barni S, Crispino S, Tancini G, Fraschini F. Endocrine and immune effects of melatonin therapy in metastatic cancer patients[J]. Eur J Cancer Clin Oncol, 1989,25(5): 789-795.
[18] Bartsch H, Bartsch C. Effect of melatonin on experimental tumors under different photoperiods and times of administration[J]. J Neural Transm, 1981, 52(4): 269-279.
[19] Lissoni P, Barni S, Mandalà M, Ardizzoia A, Paolorossi F, Vaghi M, Longarini R, Malugani F, Tancini G. Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumor patients with poor clinical status[J]. Eur J Cancer, 1999, 35(12): 1688-1692.
[20] Lissoni P, Tisi E, Barni S, Ardizzoia A, Rovelli F, Rescaldani R, Ballabio D, Benenti C, Angeli M, Tancini G, Conti A, Maestroni GJM. Biological and clinical results of aneuroimmunotherapy with interleukin-2 and the pineal hormone melatonin as a first line treatment in advanced non-small cell lung cancer[J]. Br J Cancer,1992, 66(1): 155-158.
[21] Lissoni P, Messina G, Rovelli F, Brivio F, Di Fede G. Dose-dependency of antitumor effects of the pineal hormone melatonin in untreatable metastatic solid tumor patients[J]. Int J Immunol Immunobiol,2018,1(1): 1-3.
[22] Lissoni P, Rovelli F, Brivio F, Messina G, Lissoni A, Pensato S, Di Fede G. Five year-survival with high-dose melatonin and other antitumor pineal hormones in advanced cancer patients eligible of the only palliative therapy[J]. Res J Oncol,2018, 2(1): 1-7.
[23] Nordlund JJ, Lerner AB. The effects of melatonin on skin color and on the release of pituitary hormones[J]. J Clin Endocrinol Metab,1977, 45(4): 768-774.

Copyright © 2020 Paolo Lissoni, Giorgio Porro, Carla Galli, Rosalia Codogni, Nicoletta Merli, Giuseppe Di Fede Creative Commons License Publishing time:2020-12-10
This work is licensed under a Creative Commons Attribution 4.0 International License